Hydrocutan 0.25%

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Hydrocutan 0.25%

This section defines the identity and foundational purpose of the medication, strictly based on its active components and pharmaceutical classification.

Property Description
Active ingredient Hydrocortisone
Form Cream (Dermal preparation)
Pharmacological class Corticosteroid (Glucocorticosteroid)
Common use Management of skin inflammation and itching
Origin Synthetic adrenocortical steroid

What Type of Medicine is Hydrocutan 0.25%?

Hydrocutan 0.25% is a topical preparation whose active ingredient is Hydrocortisone, a well-established synthetic adrenocortical steroid. This compound is classified within the Corticosteroid pharmacological class, specifically as a Glucocorticosteroid, designed to be effective when applied directly to the skin. Hydrocortisone is a foundational treatment, and its use in managing inflammatory skin conditions is recognized globally.

Form, Concentration, and Purpose of Hydrocutan 0.25% Cream

This medicine is typically supplied as a cream, a specific dermal preparation intended for the topical administration of the active compound. The 0.25% concentration of Hydrocortisone is a key differentiating factor, placing the product in the category of low-potency agents among topical steroids, a feature that often permits use on sensitive skin areas. Topical corticosteroids, including low-potency ones, are characterized by their anti-inflammatory and immunosuppressive actions on the skin. At this concentration, the medicine works by reducing the body's inflammatory response at the site of application. The overarching general purpose of this preparation is the localized symptomatic management of mild to moderate skin inflammation and associated discomfort, particularly pruritus (itching).

The Foundational Action of the Glucocorticoid

The primary function of the Hydrocortisone component is its action as a localized anti-inflammatory agent and an effective antipruritic agent. The mechanism involves the active ingredient penetrating skin cells and inhibiting the biochemical pathways that drive the inflammatory process, thereby reducing the production and release of localized chemical mediators. This biological response is intended to alleviate the visible signs of skin inflammation, such as redness and swelling, and simultaneously minimize the symptom of pruritus associated with various dermatoses. The rapid onset of relief is a characteristic of this class of agent.

Regulatory References

  1. NIH
Advertisements

What side effects are possible with Hydrocutan 0.25%?

Possible Side Effects and Safety Information

The information presented is based strictly on the adverse reaction data and safety classifications documented in official government regulatory documents (e.g., FDA, EMA SmPC).

Localized Skin Reactions

The most commonly listed adverse effects for this low-potency topical corticosteroid are localized skin reactions that occur at the application site. These are often classified with an Incidence Not Known frequency in official labeling but include potential effects such as burning, itching, irritation, dryness, folliculitis, and acneiform eruptions. The risk of more serious skin changes, such as skin atrophy (thinning), is explicitly associated with prolonged use.

Systemic and Serious Adverse Reactions

Although Hydrocutan 0.25% is a topical preparation, the active ingredient can be absorbed through the skin, potentially leading to systemic effects, especially with extensive use or under occlusion. The most serious adverse reactions documented in regulatory sources relate to the Endocrine System, specifically the potential for reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome. Prolonged use has also been associated with the risk of Glaucoma or Cataracts, particularly when used near the eyes. A withdrawal reaction has also been documented upon cessation after prolonged use.

Population-Specific Safety Notes

Official labeling emphasizes that the pediatric population is considered to have greater susceptibility to systemic toxicity, including HPA axis suppression and resulting growth retardation, due to a higher ratio of skin surface area to body weight. Use during pregnancy requires medical assessment, avoiding extensive use, large amounts, or prolonged periods.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Hydrocutan 0.25% (hydrocortisone) is for external use only. Overdose is primarily associated with chronic systemic absorption resulting from inappropriate use, rather than a single acute event.

Documented Risks of Overexposure

Excessive and prolonged use over large surface areas, especially under occlusive (airtight) dressings, can lead to the absorption of enough medication into the bloodstream to cause serious systemic effects. These effects include the risk of Hypercortisolism (Cushing's syndrome) and Suppression of the Hypothalamic-Pituitary-Adrenal (HPA) Axis. The HPA axis regulates the body's natural corticosteroid production. This suppression can lead to adrenal insufficiency if the medication is stopped suddenly after chronic overuse. Pediatric patients are at a higher risk for these systemic toxicities due to their larger skin surface area-to-body mass ratio.

When to Seek Emergency Medical Help

Immediate medical help must be sought if you suspect a chronic overdose or if you experience any signs of systemic toxicity, such as:

  • Sudden weight gain or rounding of the face (Moon Face)
  • Unusual fatigue or weakness
  • Swelling of the ankles or feet
  • Unexplained mood changes, agitation, or altered mental status
  • Seizures or convulsions

Treatment for chronic overexposure involves supportive care and a gradual, medically supervised withdrawal of the product to mitigate the risk of acute adrenal insufficiency.

Advertisements

Therapeutic Uses of Hydrocutan 0.25%

What Hydrocutan 0.25% Treats: Main Uses and Benefits

Hydrocutan 0.25% is a topical preparation that is applied in addressing a variety of skin conditions. This medicine is relevant in contexts marked by increased discomfort or tension due to inflammation and itching.

Topical corticosteroids are commonly used across conditions presenting with acute episodes. They are utilized for easing the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

This formulation is commonly used to help with symptoms related to physical discomfort associated with irritative skin conditions like eczema (atopic dermatitis), various forms of dermatitis, allergic skin rashes, insect bites, and mild to moderate psoriasis. It is commonly used when symptoms intensify and supportive relief is needed. The use of this type of product supports patients during episodes of heightened discomfort.

“Therapy of this type may assist with maintaining functional stability and supports general well-being during symptomatic phases.”

It provides support that helps ease the overall symptom burden, which may assist with the visible signs of inflammation (redness and swelling) and the uncomfortable feeling of itching (pruritus) that can interfere with daily comfort.

Quick Fact: Relief for Pruritus (Itching)

Regulatory References

  1. NIH DailyMed drug label information
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Hydrocutan 0.25% (Hydrocortisone topical cream) is governed by official regulatory rules that define who is eligible to use the medicine and who is absolutely prohibited. These rules are based on potential risk factors and specific co-existing conditions, as documented by authorities like the FDA and EMA.

Populations Who Must Not Use This Medicine (Contraindicated)

Classification Rule
Hypersensitivity Contraindicated in patients with a known allergy to hydrocortisone or any other component of the cream.
Local Infections Contraindicated for use on skin with untreated bacterial, viral, fungal, or parasitic infections, rosacea, acne vulgaris, perioral dermatitis, or ulcers.

Restricted-Use Populations

Classification Restriction
Pediatric Use Not recommended for use in children under 2 years of age. Use in older children is limited due to the increased risk of systemic toxicity and potential interference with growth (HPA axis suppression).
Pregnancy/Lactation Conditional use; official labeling advises use only when the benefit justifies the risk. Avoid prolonged or extensive application. Nursing mothers must avoid applying the cream to the chest area.

Eligibility is also affected by application method; occlusive dressings (including tight diapers on infants) are not advised due to the risk of increased absorption.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Hydrocutan 0.25% (topical hydrocortisone) is characterized by an absence of known drug-drug interactions under normal conditions of use. Multiple government regulatory bodies explicitly state that no known interactions are documented for this topical formulation.

Documented Interaction Constraints

While formal drug-drug interactions are not known, official labeling includes specific constraints related to systemic exposure and administration compatibility:

Interaction-Related Constraint Official Regulatory Statement
Drug-Drug Interactions None known or documented for the topical application route.
Administration Incompatibility The cream must not be mixed with other medicines in the same container due to formulation requirements.

Conditions Affecting Exposure

Regulatory documents emphasize conditions that increase systemic absorption, which is a prerequisite for any potential systemic effects or interactions. Systemic exposure risk is elevated by:

  • Occlusive Dressings: Including the use of plastic pants or diapers, which increases the percutaneous absorption of the active ingredient.
  • Large Surface Areas or Prolonged Use: Applying the cream over extensive areas of the body or for extended time periods.

Population-Specific Cautions

Pediatric patients are identified as a specific population with greater susceptibility to systemic exposure risk, such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This heightened risk is due to their body surface area-to-mass ratio.

Advertisements

Mechanism of Action

How Hydrocutan 0.25% Works

Intracellular Glucocorticoid Receptor Binding (Target & Interaction)

Hydrocutan is a synthetic corticosteroid. The active compound rapidly permeates the cell membrane to bind with high affinity to the cytosolic glucocorticoid receptor (GR). This interaction forms a ligand-receptor complex that translocates to the cell nucleus, where it functions as a transcription factor to modulate gene transcription.


Pathway Modulation and Cascade Effect (Downstream Action)

The nuclear ligand-receptor complex alters gene expression, notably leading to the inhibition of phospholipase A2 (PLA2) activity. This enzymatic inhibition subsequently restricts the synthesis of eicosanoids, a class of inflammatory mediators, including prostaglandins and leukotrienes. Furthermore, the molecular action modifies the expression of genes associated with immune response signaling and those involved in maintaining epidermal barrier function.

Advertisements

Dosage and Administration Information

How to use Hydrocutan 0.25%: Administration Guidelines

Hydrocutan 0.25% is a topical preparation that is administered according to standardized labeling. The principles of use define the route, frequency, duration, and specific procedural conditions for proper application. This information aligns with the prescribing information for topical hydrocortisone products.


Administration Scope

Entity Standardized Instructions
Route of administration Topical (Dermal application) and strictly for external use only.
Dosing schedule Applied as a thin film to the affected area. The amount used is based on the severity and extent of the condition.
Frequency pattern Two to four times daily for adults, as necessary.
Age-group rules Pediatric patients should receive the least amount compatible with an effective regimen. Use duration in children should be limited.

Resulting Procedural Structure

The instructions define a clear sequence for use:

  • Apply the cream only to the affected area of skin.
  • Use a thin film of the cream.
  • The cream is to be gently rubbed into the skin until it disappears.
  • The treated area should not be bandaged or wrapped as an occlusive dressing unless explicitly directed by a healthcare professional.
  • Use is generally short-term, intended to be discontinued once the treated condition is controlled. The regimen requires reassessment if no improvement is observed within two weeks of use.

This procedural structure outlines the administration behavior for the medication, defining the standardized approach to using the low-potency topical agent.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hydrocutan 0.25%

Evidence for Use in Atopic Dermatitis (Eczema)

Research exploring Hydrocutan 0.25% was studied for Atopic Dermatitis, a condition characterized by fluctuating or episodic manifestations. The primary sources of evidence are Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that evaluate the entire class of low-potency topical corticosteroids. These studies were designed to monitor formal outcomes related to changes in inflammation, such as EASI and IGA scores, in adult and pediatric populations with mild to moderate eczema. The studies monitored how clinical scores evolved during short-term study periods, typically lasting two to four weeks. The evidence covers the broader evidence landscape but primarily reflects what was observed under the specific, controlled conditions of the trials.

Evidence for Use in Managing Skin Itching (Pruritus)

The medicine was studied for the symptomatic management of pruritus (itching) associated with inflammatory dermatoses. Research examined the experience of adults focusing on outcomes related to physical discomfort. Studies primarily used patient-reported outcomes, where perceived discomfort was recorded using standardized scales. Findings indicate that some trials documented changes in scores measured by tools like the Visual Analogue Scale (VAS) for itching. However, certainty remains low for specific, highly localized pruritic conditions not linked to eczema, as dedicated high-quality RCTs for these particular scenarios are limited.

Areas Where Research is Still Developing

Evidence indicates that certain areas of the research landscape remain uncertain. Long-term effects are not fully established, as follow-up durations were limited in the main research. Comparative evidence is lacking in some instances, where the specific 0.25% concentration has not been widely tested against non-active creams or other non-steroidal options for every single indication. Furthermore, the results apply only to the populations studied, and data for certain comorbidity-defined groups remain insufficient.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Hydrocutan 0.25% (FAQ)

Q: Is Hydrocutan 0.25% safe to use with topical antibiotics?

A: Regulatory documents state there are no known systemic drug-drug interactions documented for topical use. However, official information indicates that this cream is stated not to be mixed with other medicines in the same container due to formulation requirements. The medicine is also contraindicated for use on skin with untreated infections.

Q: Are there specific areas of the body where Hydrocutan 0.25% should not be applied?

A: Regulatory guidance advises caution when applying the medicine to sensitive areas of the body, such as the face, groin, and armpits, because these areas are prone to higher absorption. Official warnings advise against prolonged use near the eyes due to the potential risk of effects like Glaucoma or Cataracts.

Q: Can someone use Hydrocutan 0.25% if they have a known allergy to a similar drug?

A: Official documents contraindicate use if a person has a known allergy to hydrocortisone, the active ingredient, or any component of the cream. Official guidelines specify that known allergies to similar medicines should be discussed with a healthcare provider.

Q: Do you have to stop using Hydrocutan 0.25% gradually?

A: Regulatory guidance confirms that a withdrawal reaction has been documented upon cessation after prolonged use. For this reason, the official guidance often suggests a gradual cessation process when discontinuing use after applying the medicine for an extended period.

Q: Are there different forms of Hydrocutan 0.25% available?

A: The active ingredient hydrocortisone at the 0.25% concentration may be manufactured and approved in multiple topical formulations, which can include a cream, an ointment, or a lotion. The availability of a specific form will depend on the manufacturer and the regulatory approvals within a specific region.

Q: Is Hydrocutan 0.25% used for skin rash?

A: The official purpose of the medicine is the localized symptomatic management of skin inflammation and itching, especially those associated with various inflammatory dermatoses. Many conditions that result in a 'skin rash' fall under this broad therapeutic category described in official documents.

Q: Is Hydrocutan 0.25% available over the counter?

A: The regulatory classification of this medicine depends on the specific country's regulatory authority. In some jurisdictions, the 0.25% concentration is classified as an Over-the-Counter (OTC) product, while in others, it may be available only by prescription.

Q: How quickly does Hydrocutan 0.25% start working?

A: The class of medicine, topical corticosteroids, is generally recognized for providing a relatively rapid onset of relief for inflammation and itching at the application site. Official labeling, however, does not specify an exact time frame in minutes or hours for when the initial effects should be noticed.

Q: Can Hydrocutan 0.25% interact with dietary supplements?

A: Official regulatory documents state that no known systemic drug-drug interactions are documented for the topical application of this medicine. Due to the typically low level of absorption through the skin with short-term, low-potency use, this statement generally covers supplements taken orally.

Q: Can elderly patients use Hydrocutan 0.25%?

A: Official regulatory documents do not generally indicate that elderly patients require specific dosage adjustments or have specific cautions regarding the use of this low-potency topical preparation. This contrasts with the explicit restrictions often noted for the pediatric population.

Q: What is the difference between Hydrocutan 0.25% cream and ointment?

A: Official texts describe that different bases, such as a cream versus an ointment, contain varied inactive ingredients and are designed for different absorption rates. Ointments may be more occlusive, which means they can cover the skin and potentially lead to higher absorption than creams.

Q: What should a person do if they miss an application of Hydrocutan 0.25%?

A: Official patient information addresses missed applications by describing guidance where the application is made upon remembering, unless the next application time is near. In cases where the next application time is close, the guidance suggests proceeding with the regular schedule instead of applying the missed dose.

Q: Does sun exposure affect the use of Hydrocutan 0.25%?

A: Official patient warnings sometimes advise caution against exposing the treated skin area to sunlight or artificial UV light. This is a general caution often included for topical preparations to avoid potential localized skin reactions.

Q: Can Hydrocutan 0.25% cause changes in skin color?

A: Official adverse reaction data for this class of medicine lists changes in pigmentation, such as lightening (hypopigmentation) or darkening (hyperpigmentation) of the skin, as a potential side effect. The frequency of this type of reaction is often categorized in official documents as incidence not known.

Q: What is the difference between prescription and non-prescription steroid creams?

A: Regulatory classification often distinguishes between drug products based on their potency. Lower-potency topical steroid concentrations, such as 0.25% hydrocortisone, are typically classified for Over-the-Counter (OTC) use, while higher-potency concentrations generally require a prescription.

Advertisements

How should Hydrocutan 0.25% be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation specifies strict conditions for storing and disposing of Hydrocutan 0.25% (Hydrocortisone Cream).


Storage Conditions

This medicine must be stored at Controlled Room Temperature, typically defined as 20° to 25°C (68° to 77°F). It is mandatory to protect from freezing and to avoid excessive heat and humidity to maintain product stability. The container's integrity is vital; the cream must not be used if the tamper-evident seal is broken, missing, or compromised.


Handling and Disposal

To prevent accidental exposure, the product must be kept out of the reach of children. Official disposal guidance recommends using a drug take-back program. If unavailable, the unused cream should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash; the product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hydrocutan 0.25% found in:

A-Z Index: